Philip Morris’ new scientific initiative: an analysis

In the fall of 2000, Philip Morris re-initiated an external research grants programme (“Philip Morris External Research Program”, or PMERP), the first since the dissolution of the Council for Tobacco Research (CTR) and the Center for Indoor Air Research (CIAR). The ostensible purpose of the programme is to help develop cigarette designs “that might reduce the health risk of smoking”. Internal company documents also indicate that Philip Morris urgently seeks to restore its scientific “credibility”, as part of a “new openness” in relation to the external community. The structure of the review panel—a cohort of external peer reviewers, a science advisory board, and an internal, anonymous review and approvals committee—is nearly identical to that of the CIAR. The majority of the named reviewers have had previous affiliation with the tobacco industry either as reviewers or grantees, but only a minority have done research directly on tobacco or smoking. The programmatic substance of the PMERP could be interpreted as soliciting exculpatory evidence with respect to smoking and exposure to smoke. We remain sceptical about the scientific integrity of PMERP.

Philip Morris seeks credibility and scientific integrity

An April 1998 document lists the rationale for PM’s Worldwide Scientific Affairs unit. Under the title “Reason to be”, the text notes that, among other justifications, WSA exists “to provide scientific evidence to encourage accommodation of smoker's right to smoke” and to “contribute towards rebuilding the company’s scientific credibility”. 2

A more recent WSA document lists specific strategies to attain “credibility”: “Establish a worldwide list of universities that have either private research institutions attached, or that are in close cooperation with such institutions . . . Establish a compendium of possibilities to give visual signs of the ‘new openness’ (coverage of anti conferences, sending industry papers to anti journals, seeking discussions in the public).” 3

Another 1999 document asks: “How will we improve our credibility within the scientific community in order to ensure that a balanced view is taken on smoking and health science?[emphasis in original].” 4

It is likely that PMERP is one of many steps PM has taken to use science to strengthen its legal and financial positions in the face of growing anti-industry pressure from around the world. The “new openness” in industry sponsored research may reasonably be viewed as a reaction to the damning disclosures from industry documents made available to the public through the past several years’ litigation. 5

Three essential questions need to be asked concerning PMERP: Will the funded research provide real scientific advances, or will it co-opt the scientific community into providing a “balanced view” of smoking and health issues? Will PM seek good science or exculpatory science? And, finally, why should we trust PM given that their past support of scientific research was done primarily to support a legal and public relations agenda, not to answer compelling scientific questions about tobacco and health? 6

The “Research focus”

The stated purposes of the PMERP include helping “address the concerns of the public health community regarding cigarette smoking” and enabling “PM to continue its pursuit of product modification(s) or new product design(s) that might reduce the health risk of smoking”. The January 1999 WSA draft strategic plan laid out the range of “scientific and technical issues of greatest importance” to the company [emphasis in original], such as methodology (epidemiology, study design, risk assessment), smoking and health,
smoking behaviour, and nicotine. PMERP follows these recommendations closely, but does not directly address some of the other listed scientific issues such as smoke constituents, smoke behaviour and compensation, product integrity, tobacco chemistry, and cigarette design.

The four major sets of topics that comprise the “Research focus” include:
- exposure/biomarkers/dosimetry
- epidemiological research
- clinical and model systems research
- tobacco smoke and smoking behaviour

Under “exposure/biomarkers/dosimetry”, the text notes, unexceptionally: “Exposure assessment is a necessary component in the design of reliable studies to determine health consequences of exposures... Exposure estimates classically are obtained from self-reports, area and personal monitoring, and biological monitoring with biomarkers... Biomarkers may be useful in assessing exposure as well as effects.” In the past, however, industry studies using body monitors have notoriously underestimated cumulative dosage from second hand smoke. It is troubling that, in sponsoring such studies, the PMERP may effectively be the only major source of funding for exposure research on environmental tobacco smoke in the USA. The US Environmental Protection Agency (EPA) left the field of environmental tobacco smoke (ETS) research following budget negotiations with Congress, in exchange for release of the 1992 report on second hand smoke (James Repace, former EPA researcher, and Michele Bloch, National Cancer Institute, personal communications, January 2001). No other non-industry agency, to our knowledge, currently makes dosimetry a research focus priority.

“Epidemiological research” is subdivided into: cancer of all sites; cardiovascular diseases (CVD); respiratory disease, including asthma and chronic obstructive pulmonary disease (COPD); and reproductive, maternal and placental effects. In the introduction it is stated: “Methodologically, epidemiologic studies require accurate estimates of exposure and must be designed to have the power and sensitivity necessary to test the hypothesis.”

The industry has long held the view that, with respect to second hand smoke, the epidemiological evidence of harm to non-smokers is either insufficient or is confounded by either environmental or other “lifestyle” factors, or both.

Further, the text states that: “... a number of inhalable agents such as tobacco smoke and other combustion mixtures, particulate matters, and oxidants have been implicated in the etiology or development of disease in human populations.”

It is quite conceivable that by mentioning tobacco smoke in the same breath as “other” unspecified combustion mixtures, the PMERP is attempting to dilute the perceived role of passive smoke in disease causation.

A regulatory agency typically seeks to protect public health by taking into account the preponderance of evidence (cellular toxicology, animal exposures, human epidemiology) in assessing the risk posed by a substance, particularly in the case of agents acting at low doses over an extended period of time. By contrast, however, the tobacco industry criticised the US EPA report, the US Occupational Safety and Health Administration (OSHA) rules proposed for workplace smoking, and the International Agency for Research on Cancer (IARC) study on second hand smoke, demanding precise, biomarker evidence in humans but rejecting nicotine and cotinine as appropriate biomarkers.

PM does not accept that second hand smoke is a causal hazard to health, a position similar to the one it held on direct smoking until its public admission in October 2000.

With respect to cancer, PMERP states: “Epidemiological research is needed to identify external and internal risk factors for the development of cancer of all sites as well as to characterize the independence or confounding potential of factors operating within complex multi-path biological systems.” For decades the industry has asserted that along with several confounding variables such as diet and lifestyle, tobacco was merely another “risk factor” for cancer. It was only in October 2000 that PM unequivocally acknowledged that tobacco smoking causes cancer, and by known biological mechanisms. The PMERP request for proposals seems to suggest further research on “confounding” variables that might, at least partially, exculpate tobacco—a scientific stance critical to the defence in current and future lawsuits against the industry.

The text acknowledges that cardiovascular disease “represents the largest, single contribution to morbidity and mortality in developed countries”. Notably, the tobacco industry, in its attack on worldwide tobacco control efforts, insists that developing countries do not face the same morbidity and mortality from tobacco related diseases. This is despite World Health Organization predictions that by 2020 tobacco attributable deaths worldwide will correspond to 12.3% of all deaths— surpassing diarrhoeal diseases, perinatal diseases, and tuberculosis—and that by 2030 70% of tobacco related deaths will occur in the developing world.

As for “reproductive health”, the text suggests that there may be some substances in “complex mixtures such as tobacco smoke [which] have been implicated in the causation of reproductive and developmental health effects such as low birth weight”. This may be taken to suggest that some components in the complex mixture are the actual cause of low birth weight and, if removed, could conceivably allow pregnant women to continue smoking without placing their fetuses at risk, congruent with the industry’s research on product modification.

Similarly, in the “clinical and model systems research” section, it is implied that if the precise interactions of agent (smoke) and host were understood, health risks could be reduced by modifying one or better equipping the
other. The document indicates a particular interest in research proposals that emphasise host susceptibility, genetic factors, and molecular and cellular mechanisms of disease. For cardiovascular diseases, proposals to study cellular, biochemical, and molecular mechanisms and “relevant smoke constituents” are welcomed, as these would lead to an examination of the physiological chain of events by which inhaling “particle and vapor phase constituents” induces a generalised inflammatory response as the proximal cause of a “coronary event”.

This section holds the most interest for those who believe that a safer cigarette would be possible only if only the “relevant” constituents of tobacco’s “complex mixture”, as they relate to the aetiology of cancer, cardiovascular disease, respiratory diseases, and other illnesses, could be identified and eliminated.

The final section, “tobacco smoke and smoking behavior”, principally requests research proposals on topics like “the role of nicotine and/or other substances as determinants of smoke exposure” and “brain activity measured differentially with modern imaging techniques, in order to understand neural processes occurring before, during and after smoking”. It also calls for studies to characterise “pharmacologically active constituents of tobacco smoke . . . ” other than nicotine. No mention is made of research on how to conquer nicotine addiction.

The PMERP research focus therefore describes a detailed approach to understanding tobacco’s role in human disease—one not much different from that of the US National Cancer Institute's (NCI) Tobacco Research Implementation Plan, published in 1998. However, the NCI's research agenda is more comprehensive in that it also includes research on cessation, community level interventions, surveillance, and policy. The plan's biomedical research is just getting underway, but does not yet include work on second hand smoke. What is more important to ask is whether a tobacco company can be relied upon to sponsor, promote, and disseminate credible study findings. In the past, tobacco industry sponsored research was used to advance the industry's political agenda and has not always passed the test of scientific integrity. Whether or not the research generated by PMERP will be different, remains to be seen.

“Research and review process overview”
PMERP’s structure is the same as that of the now defunct CIAR. Indeed, the texts of the 1998 CIAR request for applications and of the PMERP request for applications are almost identical, except that CIAR’s focus was on problems related to indoor air quality while PMERP’s mandate is substantially broader.

In both cases, there is a science advisory board (SAB) and the PMERP document lists six persons as SAB members. All are well published senior scientists, and three of them have had past associations with CIAR. The SAB makes recommendations for funding based on the evaluation of the peer reviewers. A concern is that final funding decisions, both at the former CIAR and at PMERP, rest with the tobacco industry, raising questions regarding the integrity and independence of the grant process. This issue was in fact raised by Helmut Reif, director of science and technology at PM’s research and development unit in Neuchatel, Switzerland, when commenting on the proposal for the creation of a new corporation to fund indoor air quality research, in the wake of CIAR’s closing. Regarding the authority of a board of directors to have final approval of funding, Reif stated: “Here, I fear, we have the same disputable situation as with CIAR, that the SAB wants or does not want something, decides after lengthy discussions, and finally is overruled by the Board of Directors? Can we ensure that the scientific opinion of the SAB would carry some weight? Otherwise they might feel bad and possibly quit.”

The members of the PM scientific research review committee, which has the final funding authority, are not identified in the PMERP application document, but their role is to assure the company that all funded studies meet “the highest scientific, ethical, and legal standards and serve relevant business needs.” The January 1999 draft of WSA's strategic plan stated that one of the WSA's roles was to: “. . . manage the Scientific Research Review Committee’s review and approval of all tobacco, smoke and/or smoking related scientific studies conducted or funded by Philip Morris Companies.”

Similarly, a body known as the “Research management group” is charged with managing PMERP. It has the same address as CIAR in Maryland, USA, and former CIAR director Max Eisenberg is the designated contact person for all inquiries about the programme.

Profile of the peer reviewers
It is impossible to determine which reviewers PM will actually select. But PM's publication of the names and affiliations of 105 potential reviewers is revealing. During the month of November 2000, we searched Medline to count the number of papers authored or co-authored by each individual (see below), and computed the ratio of tobacco, smoke and/or smoking related scientific studies conducted or funded by Philip Morris Companies. We also used Internet search engines Monster Crawler, Yahoo and Google to confirm each peer reviewer's name, institution, department and, where possible, area(s) of expertise/specialty. Additionally, we searched on the potential reviewers' names in the databases of the tobacco industry documents that are available on the Internet. By this method, we were able to ascertain previous connections between peer reviewers and industry sponsored research efforts. Tables 1 and 2 summarise our findings. (Our total count is a close estimate as some persons with common names have namesakes writing in completely different specialties, and a thorough effort has been made to screen these out. A handful of reviewers co-authored papers
Table 1  Peer reviewers’ profile

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degree</td>
<td></td>
</tr>
<tr>
<td>PhD</td>
<td>82 (78)</td>
</tr>
<tr>
<td>MD</td>
<td>19* (18)</td>
</tr>
<tr>
<td>Other</td>
<td>4 (4)</td>
</tr>
<tr>
<td>Affiliation</td>
<td></td>
</tr>
<tr>
<td>University</td>
<td>79 (75)</td>
</tr>
<tr>
<td>US EPA</td>
<td>61 (6)</td>
</tr>
<tr>
<td>Retired PM scientist</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Other</td>
<td>173 (16)</td>
</tr>
<tr>
<td>Specialty</td>
<td></td>
</tr>
<tr>
<td>Air pollutant and air quality research</td>
<td>46 (44)</td>
</tr>
<tr>
<td>Asthma/immunology/allergy</td>
<td>17 (15)</td>
</tr>
<tr>
<td>Pulmonary and respiratory diseases</td>
<td>13 (12)</td>
</tr>
<tr>
<td>Molecular and tumour toxicology</td>
<td>7 (6)</td>
</tr>
<tr>
<td>Alzheimer’s disease</td>
<td>4 (4)</td>
</tr>
<tr>
<td>Drug metabolism</td>
<td>45 (4)</td>
</tr>
<tr>
<td>Risk assessment</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Genetics</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Epidemiology/statistics</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Other</td>
<td>5 (5)</td>
</tr>
<tr>
<td>Previous connection with the tobacco industry</td>
<td></td>
</tr>
<tr>
<td>CIAR grantee</td>
<td>53 (50)</td>
</tr>
<tr>
<td>CIAR listed peer reviewer</td>
<td>22 (21)</td>
</tr>
<tr>
<td>CIAR grant applicant</td>
<td>3 (3)</td>
</tr>
<tr>
<td>CIAR funded project co-author</td>
<td>5 (5)</td>
</tr>
<tr>
<td>Other tobacco industry funding relationship</td>
<td>56 (5)</td>
</tr>
<tr>
<td>No previous tobacco industry connection</td>
<td>17 (15)</td>
</tr>
</tbody>
</table>

*Four of whom have PhD
†One is a consultant to the US Environmental Protection Agency (EPA).
‡Includes three people from US National Institutes of Health and three people from Oak Ridge National Laboratory.
§Only one working in nicotine chemistry/metabolism.
¶Three are retired PM scientists.
CIAR, Center for Indoor Air Research; PM, Philip Morris.

with each other and these papers were counted twice. Some reviewers have also written for peer reviewed journals outside of Medline’s purview.

Table 2 describes the publication record of the peer reviewers in Medline. Publication dates extend from the 1950s to the present, but the majority fall within the past 15 years. Ninety per cent (n = 94) of the reviewers had papers published on Medline indexed journals, with a total of 4502 publications. The total number of tobacco related publications (determined by using the MeSH terms described earlier) is 298, 7% of the total Medline publications. Forty eight (51%) of the peer reviewers with publications indexed on Medline had no tobacco related publications and only 20 (19%) of the 94 had published 10% or more of their papers on topics related to tobacco and smoking. By comparison, the six members of the SAB have an average of 191 articles on Medline (range 94–366), with four having 10% or more on tobacco related topics (range 1–98).

This analysis shows that the PMERP has many similarities with the structure of CIAR. In its day CIAR was not an independent and objective enterprise. CIAR’s structure, and its sponsored studies and publications, were used aggressively by the tobacco industry to counteract and subvert the conclusions of the IARC study on second hand smoke, to provide evidence in regulatory agency hearings, and to battle legislative efforts to pass clean indoor air measures.

As Barnes and Bero have shown, CIAR funded two types of projects: peer reviewed and special reviewed. The CIAR review process was used to serve the industry’s political and legal interests, with peer review projects serving to “enhance its [tobacco industry] credibility” and to “divert attention of ET’s as an indoor air pollutant”.

Projects approved directly by tobacco company executives through the special review process were more likely to produce exculpatory evidence on second hand smoke that could then be used by the industry in litigious and legislative efforts against public smoking bans.

Since the review structure for the PMERP gives final say on funding decisions to the unidentified “Philip Morris scientific research review committee” and not to the SAB, the same biased outcome may occur. In addition, CIAR was known to use its sponsored symposia to produce publications favouring the industry’s position. It is unknown if PMERP sponsored special projects, workshops, and conferences will serve the same purposes, but it is important to note that, in the past, industry academic sponsorship has often translated into industry biased science.

While we do not know which peer reviewers will ultimately be used, the proposed reviewers’ relative lack of expertise in tobacco research, as ascertained by the Medline search, is also not reassuring.

We caution here that a scientist’s past affiliation with the CIAR or with the new PMREP does not necessarily mean that the individual is openly, secretly or even naively pro-tobacco, as was often the case in the example of...
“Operation Whitecoat.”

For instance, when US Congress staff polled nine members of the CIAR science advisory board in 1994, six of the seven respondents agreed that environmental tobacco smoke was a serious threat to children, and five agreed that it was a pulmonary carcinogen. Since the release of the request for applications, Essential Action, a nongovernmental organization (NGO), has sponsored a letter writing campaign to pressure peer reviewers to have their names withdrawn from the list. Approximately 15% of the reviewers have agreed to Essential Action’s request. Scientists accepting tobacco industry funding must consider the ethics of their actions. There is no evidence that PM will do anything other than continue its practice of attempting to establish credibility and legitimacy through the utilization of outside scientists and institutions, a strategy also practiced by British American Tobacco.

In the wake of CIAR’s extinction, PM has shown apparent concern with the continuity of its programmes, and is interested in pursuing its partnerships with academic institutions. While the MSA provided for the dissolution of CIAR, it did not bar the possibility of reconstitution under a new name, as it did specifically with CTR. In fact, in March of 1999, PM was apparently considering a “Proposal for formulation of a corporation to support indoor air research”, with a structure similar to that of the CIAR. While we do not know if PM will create this non-profit research corporation, it is clear that the mission and objectives of PMERP, and that of its “manager”, the Research management group, are intended to serve the same dual purpose of establishing partnerships and gaining scientific credibility.

Our review of the PMERP suggests that it represents the continuation of industry sponsored research through a structure that resembles the CIAR. We can legitimately question whether tobacco industry science will be converted to tobacco industry marketing, keeping “controversy alive” and thus continuing to threaten public health. We will not know PMERP’s true impact until the research projects are approved, conducted and published in peer reviewed journals but, in the meantime, we can urge scientific and professional journals to expand their funding disclosure policies, so it will be possible to monitor the research that PM is sponsoring. We also urge granting agencies, unencumbered by the tobacco industry’s burdensome motives, to continue to support and expand research programmes that respect the public health mandate to learn absolutely everything that can be known about tobacco smoking and health.

NORBERT HIRSCHHORN
STELLA AGUINAGA BIALOUSS
STAN SHATENSTEIN

Correspondence to: Dr Norbert Hirschhorn, 1044 Chapel Street, Apartment, 302, New Haven, CT 06510, USA; bertgoet@yahoo.com

Contributors: Norbert Hirschhorn, Stella Aguinaga Bialous, and Stan Shatenstein analyzed peer reviewers’ profiles and wrote the paper; Sneed Jones, Pnton Howard, and Stephen Humann analyzed peer reviewers’ profiles.

1 Master Settlement Agreement; 1998. www.naag.org/tobacopubliclibrary.cim
5 Action on Smoking and Health UK. Tobacco explained: the truth about the tobacco industry ... in its own words. London: ASH-UK; 1998:9
14 Pa J, Chaloupka F, eds. Tobacco control in developing countries. Oxford University Press, 2000
15 Institute of Medicine. Control of cardiovascular disease in developing countries: research, development, and institutional strengthening. Institute of Medicine, 1998
17 Satcher D. Why we need an international agreement on tobacco control. Am J Public Health 2001;91:162–4
19 Hirschhorn N. Shameful science: four decades of the German tobacco industry’s hidden research on smoking and health. Tobacco Control 2000;9:242–7
31 Barnes D, Ber L. Industry-funded research and conflict of interest: an analysis of research sponsored by the tobacco industry through the Center for Indoor Air Research. J Health Politic Policy Law 1996;21:515–42

The Chesterfield Yamaha grand prix motorcycling team happy at their latest efforts to advertise Chesterfield to the world’s adult smokers, and Play Station (see their upper sleeves) to the world’s children. The idea is that children selectively perceive the Play Station ads, but not the Chesterfield ads. Makes sense, huh?